Real-world evidence on intravenous eptinezumab in patients with episodic migraine

Puntos clave

• Intravenous eptinezumab significantly reduces migraine days per month, enhancing patient quality of life.
• Patients reported a mean reduction of 6.2 migraine days within three months of treatment initiation.
• Real-world evidence was collected from diverse healthcare settings, highlighting clinical benefits of the intervention.
• These findings support the potential of eptinezumab as an effective treatment option for episodic migraine.